These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 32241817)

  • 1. Identification of Deleterious
    Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
    Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
    Mazzotta M; Filetti M; Occhipinti M; Marinelli D; Scalera S; Terrenato I; Sperati F; Pallocca M; Rizzo F; Gelibter A; Botticelli A; Scafetta G; Di Napoli A; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Fanciulli M; De Nicola F; Ciuffreda L; Goeman F; De Maria R; Vecchione A; Giusti R; Ciliberto G; Marchetti P; Maugeri-Saccà M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of
    Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
    JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
    Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
    Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
    Zheng J; Deng Y; Huang B; Chen X
    Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
    Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.
    Gao R; Lou N; Li L; Xie T; Xing P; Tang L; Yao J; Han X; Shi Y
    J Transl Med; 2024 Jun; 22(1):576. PubMed ID: 38890738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
    Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
    ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.